Related Experiment Video
Updated: Aug 16, 2026
Multimodality Diagnosis of Mesenteric Ischemia
Published on: July 21, 2023
Prevalence of prothrombotic abnormalities in patients with acute mesenteric ischemia
Nazim Ağaoğlu1, Serdar Türkyilmaz, Ercüment Ovali
1Department of General Surgery, Karadeniz Technical University, Faculty of Medicine, Trabzon 61080, Turkey. nagaoglu@meds.ku.edu.tr
Abstract:
Acute mesenteric ischemia (AMI) is a rare condition that may be associated with a variety of congenital prothrombotic disorders (PDs). The purpose of this study was to assess the prevalence of these disorders in 28 AMI patients compared with 103 healthy individuals from the northeastern region of Turkey. They were screened for protein C, antithrombin III, and protein S deficiencies; and gene analysis was performed using the polymerase chain reaction. A PD was revealed in 16 (57%) patients and 33 (32%) controls (p = 0.020). Factor V Leiden (FVL), prothrombin G20210A mutation, and TT677 homozygous mutation of methylenetetrahydrofolate reductase was detected in 10 (36%) patients versus 16 (15%) controls (p = 0.035), 3 (11%) patients versus 10 (9%) controls (p = 1.00), and 1 (3%) patient versus no controls, respectively. Consistent with caucasian ethnic groups, there was high prevalence of PDs, especially FVL; and these abnormalities might be a significant predisposing factor in the pathogenesis of AMI.
Insights
Prothrombotic disorders (PDs) are more common in acute mesenteric ischemia (AMI) patients than healthy individuals. Factor V Leiden mutation was a particularly prevalent PD in AMI patients, suggesting a role in disease development.
Area of Science:
- Vascular Medicine
- Genetics
- Gastroenterology
Background:
- Acute mesenteric ischemia (AMI) is a rare but serious condition.
- Congenital prothrombotic disorders (PDs) are potential risk factors for AMI.
- Understanding the prevalence of PDs in AMI is crucial for risk stratification and prevention.
Purpose of the Study:
- To determine the prevalence of congenital prothrombotic disorders in patients with AMI.
- To compare the frequency of PDs in AMI patients versus a healthy control group.
- To investigate specific PDs, such as Factor V Leiden mutation, as potential contributors to AMI pathogenesis.
Main Methods:
- Screening of 28 AMI patients and 103 healthy controls from northeastern Turkey.
- Testing for deficiencies in protein C, antithrombin III, and protein S.
- Gene analysis using polymerase chain reaction (PCR) for specific mutations.
Main Results:
- Prothrombotic disorders were found in 57% of AMI patients compared to 32% of controls (p=0.020).
- Factor V Leiden (FVL) mutation was significantly more frequent in AMI patients (36%) than controls (15%) (p=0.035).
- Prothrombin G20210A mutation and MTHFR TT677 homozygous mutation showed no significant difference between groups.
Conclusions:
- Congenital prothrombotic disorders are significantly more prevalent in patients with acute mesenteric ischemia.
- Factor V Leiden mutation is a notable predisposing factor in the pathogenesis of AMI.
- These findings highlight the importance of screening for PDs in individuals at risk for AMI.
